Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib First-line Maintenance in Extensive-stage Small Cell Lung Cancer (Phase II)
ChiCTR2200060985Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in small cell lung cancer (SCLC), sponsored by Second Hospital of Shandong University. Primary endpoint: Progression-free survival. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2200060985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060985.